Search clinical trials for: GVHD treatment

Total 63525 results

Xuzhou Medical University

Not yet recruiting

Safety and Efficacy of Treg Cell in the Treatment of GVHD

GVHD
ReAlta Life Sciences, Inc.

Not yet recruiting

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease (AURORA)

Steroid Refractory GVHD
Wang Xin

Not yet recruiting

Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT

GVHD

China
Fundación Oftalmológica de Santander Clínica Carlos...
Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS

Not yet recruiting

Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment (GvHD)

Graft Versus Host Disease
Xuzhou Medical University

Recruiting

Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD

cGVHD

China
Beijing Tide Pharmaceutical Co., Ltd

Not yet recruiting

TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))

GVHD, Chronic
Central Hospital, Nancy, France

Not yet recruiting

Steroids Versus ECP and Steroids as First-line Treatment of Grade II Acute GVHD (COPAVEHDI)

Graft Vs Host Disease

France
Peking University People's Hospital

Recruiting

Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD

Acute Graft Versus Host Disease

China
St. Jude Children's Research Hospital

Recruiting

A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies

Hematologic Malignancy | Myeloid Malignancy

United States
The First Affiliated Hospital of Soochow University

Recruiting

GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT

Aplastic Anemia

China
Equillium
Biocon Limited

Recruiting

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

Graft Versus Host Disease | GVHD | aGVHD | Acute-graft-versus-host Disease | Acute GVHD

United States, Korea, Republic of, Germany, Israel, Spain, Belgium, Italy, Australia, France, Canada, Portugal, New Zealand
The First Affiliated Hospital of Soochow University
The Second People's Hospital of Huai'an; Soochow Hopes Hematonosis Hospital

Recruiting

Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD

Safety and Efficacy

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Acute Graft-Versus-Host Disease

China
Peking University People's Hospital

Recruiting

MTX and Steroid for III-IV aGVHD Treatment

Acute Graft Versus Host Disease

China
Medical University of Graz

Recruiting

Study on the Treatment With Water-filtered Infrared-A (wIRA) Radiation in Patients With Morphea and Sclerotic Graft-versus-host Disease

Morphea (Circumscribed Scleroderma) | Sclerotic Graft-versus-host Disease (GVHD)

Austria
Tata Memorial Centre

Recruiting

Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant

Musculoskeletal Disease Other | GVHD, Chronic

India
Peking University People's Hospital

Recruiting

MTX and Steroid for aGVHD Treatment

Acute GVH Disease

China
Universitätsklinikum Hamburg-Eppendorf
Mallinckrodt; University Medical Center Regensburg; Arbeitskreis Klinische Forschung...

Recruiting

Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease

Acute-graft-versus-host Disease

Germany, Austria
St. Petersburg State Pavlov Medical University

Recruiting

Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD (JAK-FMT)

Intestinal GVHD

Russian Federation
Mats Remberger
The Swedish Research Council

Recruiting

Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT (2017-00355)

GVHD, Acute

Sweden, Norway, Denmark
AHS Cancer Control Alberta

Recruiting

HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis (ATG2017)

Relapse | Graft-versus-host-disease

Canada
Washington University School of Medicine
St. Louis Children's Hospital

Recruiting

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

Hemoglobinopathies | Metabolic Disorders | Hematologic, Immune, or Bone Marrow Disorders | Non-malignant Disorders

United States, Canada
University of Liege
KU Leuven; Maastricht University Medical Center; University Hospital, Ghent; Queen... and other collaborators

Recruiting

Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function

Graft-versus-host Disease | Poor Graft Function | Low Donor T-cell Chimerism

Belgium, Netherlands
Dimitrios Tzachanis, MD PhD
Bristol-Myers Squibb

Active, not recruiting

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

Hematologic Neoplasms | GVHD

United States
CSL Behring
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Active, not recruiting

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Graft Versus Host Disease (GVHD)

United States
University of Utah
Incyte Corporation

Terminated

Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD (FLIGHT)

Chronic Graft-versus-host-disease

United States
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids (MTX-aGVHD)

Stem Cell Transplant Complications | GVHD, Acute | GVH - Graft Versus Host Reaction | Allogeneic Disease

France
Cytopeutics Sdn. Bhd.
Universiti Tunku Abdul Rahman

Active, not recruiting

UCMSCs as Front-line Approach of Treatment for Patients With aGVHD (GVHD Cyto-MSC)

Acute-graft-versus-host Disease

Malaysia
University of Freiburg

Completed

Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients

Graft Versus Host Disease

Germany
Kaohsiung Veterans General Hospital.
Kaohsiung Medical University Chung-Ho Memorial Hospital

Completed

Personalized Treatment for Refractory H Pylori Infection

Helicobacter Pylori Infection

Taiwan
Jonsson Comprehensive Cancer Center

Withdrawn

Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

Acute Graft Versus Host Disease | Gastrointestinal Tract Acute Graft Versus Host Disease | Severe Gastrointestinal Tract Acute Graft Versus Host Disease | Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease

United States
Washington University School of Medicine

Withdrawn

Vigamox Treatment for Ocular Graft-Versus-Host Disease

Ocular Graft-versus-host Disease

United States
Dartmouth-Hitchcock Medical Center

Active, not recruiting

Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment

Cutaneous T Cell Lymphoma | Graft Versus Host Disease

United States
University of Utah

Completed

Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)

Ocular Graft Versus Host Disease

United States
Novartis Pharmaceuticals

Completed

Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

Acute Graft Versus Host Disease

Belgium, Japan, Spain, France, Korea, Republic of, Canada, Italy, Denmark
Peking University People's Hospital
Sun Yat-sen University; Third Military Medical University; Southern Medical University...

Completed

Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT

Graft Vs Host Disease

China
Incyte Corporation

Terminated

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

Acute Graft-versus-host Disease

United States, Spain, France, Italy, United Kingdom, Germany
Xenikos
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (2002)

Steroid-Refractory Acute Graft Versus Host Disease

United States, Belgium, Croatia, France, Germany, Italy, Netherlands, Spain, United Kingdom
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

Graft-versus-Host Disease | Immune System Disorders

United States
Ciceri Fabio

Completed

Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole (SIR-POSA)

Myelodysplastic Syndromes | Fungal Infection | Graft Vs Host Disease | Leukemia, Acute | Transplant-Related Hematologic Malignancy

Italy
Leland Metheny

Withdrawn

Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD

Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)

United States
Incyte Corporation

Approved for marketing

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Graft-versus-host Disease (GVHD)

United States
Kiadis Pharma

Terminated

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer (HATCY)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States, Canada, Netherlands, Israel, Germany, United Kingdom, Belgium, Italy, Sweden, Croatia, Spain, France, Portugal
Medsenic

Completed

Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide (GvHD-ATO)

Immune System Diseases | Chronic Graft-Versus-Host Disease
Peking University Third Hospital

Completed

Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment

Graft Versus Host Disease in Eye

China
Mesoblast, Inc.
Quintiles, Inc.

Completed

A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)

Grade B aGVHD | Grade C aGVHD | Grade D aGVHD

United States
Mesoblast, Inc.
Quintiles, Inc.

Completed

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Grade B Acute Graft Versus Host Disease | Grade C Acute Graft Versus Host Disease | Grade D Acute Graft Versus Host Disease

United States
Mesoblast, Inc.

Completed

Safety and Efficacy of Prochymal® for the Salvage of Treatment-Refractory Acute GVHD Patients

Graft Versus Host Disease

United States
Mesoblast, Inc.

Completed

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

Graft Versus Host Disease

United States, Australia, Canada
Xenikos
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) (1802)

Steroid-Refractory Acute Graft Versus Host Disease

United States

Search clinical trials for: GVHD treatment

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations